OpenAI and Anthropic, which had existing evaluation partnerships with the center dating to 2024, renegotiated their deals to align with priorities in Trump's AI Action Plan.
“Terafab is likely an Intel fab expansion, with Tesla, SpaceX, and xAI as anchor customers, rather than a standalone venture,” said Yole analyst Adrien Sánchez.